Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ann Arbor, MI, US. The stock last traded at $3.18, up 0.00% on the session, giving a market capitalisation of $661.1M. On trailing twelve-month figures it carries a trailing P/E of -131.40, a net margin of -1.8%. Its beta of 1.06 implies it has historically moved more than the broad market.
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Esperion Therapeutics, Inc. is most often compared with the following Healthcare names: